Ascletis Pharma Inc. (01672) said it was informed by the executive directors and controlling shareholders of the company, Dr Jinzi Jason Wu and Mrs Judy Hejingdao Wu, that they have jointly purchased in aggregate of 2.31 million shares of the company on the open market for an aggregate consideration of HK$6.99 million (representing an average price of HK$3.02 per share).
Immediately following the Purchase, they are interested in an aggregate of 599.53 million shares (before the purchase: 597.22 million shares), representing approximately 53.50% (before the purchase: 53.29%) of the total issued share capital of the company.
etnet榮獲HKEX Awards 2023 「最佳表現證券數據供應商」大獎► 了解詳情